Table 1.
Basic characteristics of patients
| Study(year) | Study design | Treatment | Country | Patients | AGE | Sex(M/F) | Tumor size(cm) (<5/≥5) | Tumor Number (S/M) | aType of PVTT (I/II/III/IV) | Child-Pugh (A/B/C) | Virology HBV/Other | Cirrhosis (Yes/No) | Total bilirubin level (μmol/L) | Serum albumin level (g/L) | AFP(mg/L) (<400/≥400) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Fan 2001 [20] | R(1996-1998) | HR | China | 74 | 48.2(20-70) | NA | 35/39 (≥10/<10) | 46/28 | 0/58/16/0 | NA | NA | NA | NA | NA | NA |
| TACE | 18 | 48.2(20-70) | NA | 13/5(≥10/<10) | 13/5 | 0/12/6/0 | NA | NA | NA | NA | NA | NA | |||
| Fan 2003 [19] | R(1997-2000) | HR | China | 19 | 47 (26-75) (All)b | 122/16 (All) |
9/10 (≥10/<10) | 10/9 | 0/14/5/0 | 105/33/0 (All) | 103/35 (All) |
NA | NA | NA | 108/30 (≥10/<10) ng/ml(All) |
| TACE | 41 | 47 (26-75) (All) |
122/16 (All) |
21/20 (≥10/<10) | 26/15 | 0/26/15/0 | 105/33/0 (All) | 103/35 (All) |
NA | NA | NA | 108/30 (≥10/<10) ng/ml(All) |
|||
| Cheng 2005 [18] | R(2000-2003) | HR | China | 7 | 47.5 ± 6.9 | 5/2 | 62.7 ± 49.8 (mm) | 7/0 | 2/4/1/0 | NA | 6/1/ | NA | NA | NA | 5/2(≥20/<20) μg/L |
| TACE | 38 | 47.9 ± 10.6 | 35/3 | 62.7 ± 49.8 (mm) | 30/8 | 6/11/20/1 | NA | 32/6 | NA | NA | NA | 28/10 (≥20/<20)μg/L |
|||
| Fan 2005 [21] | R(1997-2002) | HR | China | 24 | 15/9 (≥45/<45) |
20/4 | 11/13 (≥10/<10) | 14/10 | 0/16/8/0 | 18/6/0 | NA | NA | NA | NA | NA |
| TACE | 53 | 25/28 (≥45/<45) |
49/4 | 28/25 (≥10/<10) | 33/20 | 0/30/23/0 | 39/14/0 | NA | NA | NA | NA | NA | |||
| Zhou 2011 [25] | R(2003-2010) | HR | China | 38 | 22/16 (≥50/<50) |
35/3 | 13/25 | 27/11 | 0/25/13/0 | 27/11/0 | 36/2 | 14/24 | NA | NA | 14/24 |
| TACE | 10 | 5/5 (≥50/<50) |
10/0 | 8/2 | 3/7 | 0/4/6/0 | 4/6/0 | 10/0 | 9/1 | NA | NA | 1/9 | |||
| Peng 2012 [12] | R(2002-2007) | HR | HongKong China |
201 | 55 (25-75) | 187/14 | 76/125 | 95/106 | 27/68/83/23 | 197/4/0 | 172/27 | 176/25 | 12.9 | 36.8 | 562.3 |
| TACE | 402 | 55 (23-75) | 374/28 | 178/224 | 132/270 | 54/136/166/46 | 389/13/0 | 356/46 | 363/39c | 12.5 | 36.3 | 598.5 | |||
| Liu PH 2014 [22] | R(2002-2012) | HR | Taiwan USA |
108 | 62 ± 15 | 91/17 | NA | 57/51 | NA | 91/17/0 | 50/58 | NA | 0.9 ± 0.9 (mg/dL) |
38 ± 5 | 19,532 ± 55,912 (ng/mL) |
| TACE | 108 | 61 ± 14 | 84/24 | NA | 56/52 | NA | 95/13/0 | 49/59 | NA | 1.0 ± 0.6 (mg/dL) |
38 ± 4 | 32,725 ± 138,234 (ng/mL) |
|||
| Liu K 2014 [17] | R(2003-2010) | HR | China | 41 | 48.7 ± 10.2 | NA | 9.3 ± 2.7 | 41/0 | 12/21/3/0 | 35/6/0 | 32/9 | NA | 28.5 ± 11.0 | 39.2 ± 6.1 | 10/31 |
| TACE | 72 | 49.7 ± 10.2 | NA | 10.5 ± 3.6 | 72/0 | 24/32/16/0 | 59/13/0 | 60/12 | NA | 29.3 ± 11.5 | 38.4 ± 5.1 | 16/56 | |||
| Ye 2014 [24] | R(2007-2009) | HR | China | 90 | 49.3 ± 10.7 | 81/9 | 6.9 ± 1.6 | 51/39 | 0/66/24/0 | 84/6/0 | 12/78 | NA | NA | NA | 48/42 |
| TACE | 86 | 45.6 ± 10.2 | 80/6 | 6.5 ± 2.7 | 32/54 | 0/66/20/0 | 78/8/0 | 18/68 | NA | NA | NA | 38/48 | |||
| Lee 2016 [13] | R(2000-2011) | HR | Korea | 40 | 55.0 ± 12.9 | 30/10 | 20/20 | NA | 0/26/14/0 | 35/5/0 | 31/9 | 27/13 | 0.9 ± 0.9 (mg/dL) |
40 ± 0.6 | 10,728 ± 25,073 (ng/mL) |
| TACE | 80 | 58.3 ± 10.5 | 67/13 | 10/70 | NA | 0/31/49/0 | 58/22/0 | 54/26 | 73/7 | 1.3 ± 1.3 (mg/dL) | 36 ± 0.5 | 27,302 ± 71,902 (ng/mL) | |||
| Zheng 2016 [1] | R(2000-2008) | HR | China | 96 | 51.9 ± 14.3 | 75/21 | 7.9 ± 2.2 | 2.4 ± 1.4 | 25/23/23/25 | 75/21/0 | 86/10 | 82/14 | NA | NA | 1120.6 ± 3930.7 (ng/mL) |
| TACE | 134 | 51.6 ± 13.3 | 98/36 | 8.0 ± 2.4 | 2.7 ± 1.8 | 31/32/33/38 | 101/33/0 | 117/17 | 118/16 | NA | NA | 1222.2 ± 2698.1 (ng/mL) |
|||
| Wang 2016 [11] | R(2002-2014) | HR | HongKong China | 745 | 305/440 (≥50/<50) |
679/66 | 138/607 | 693/52 | 263/351/194/0 | 737/8/0 | 670/75 | 513/232 | 543/202 (<18.8/≥18.8) | 47/698 (<35/≥35) | 274/471 |
| TACE | 604 | 319/285 (≥50/<50) |
534/70 | 79/525 | 474/130 | 47/288/269/0 | 567/37/0 | 125/479 | 473/131 | 353/251 (<18.8/≥18.8) |
130/474 (<35/≥35) |
230/374 |
R (1996-1998): Retrospective study and the time of patients included in case-control cohort, NA Not applicable, TACE Transarterial chemoembolization, HR Hepatic resection
aThe type of PVTT was performed by Cheng’s classification [26, 27]. b All means data from all included patients, of whom were in HR and TACE group partially